



## Number of Drugs under Consideration by pCPA, 3-month quarterly Average, Q1 2019 – Q4 2023



\* Does not include drugs where negotiations were not pursued or subsequent pCPA attempts after the first attempt


Source: IMC analysis of pCPA data collected from <https://www.pcpacanada.ca/negotiations> and CADTH data collected from <https://cadth.ca/reimbursement-review-reports>.

## Number of new pCPA Negotiations



Source: IMC analysis of pCPA data collected from <https://www.pcpacanada.ca/negotiations> and CADTH data collected from <https://cadth.ca/reimbursement-review-reports>.


## CADTH Recommendation to pCPA Engagement, All Drugs



\* Does not include drugs where negotiations were not pursued or subsequent pCPA attempts after the first attempt


Source: IMC analysis of pCPA data collected from <https://www.pcpacanada.ca/negotiations> and CADTH data collected from <https://cadth.ca/reimbursement-review-reports>.

## Number of Active pCPA Negotiations, 3-month Quarterly Average, Q1 2019 – Q4 2023




Source: IMC analysis of pCPA data collected from <https://www.pcpacanada.ca/negotiations>.

## Number of Active pCPA Negotiations and Files Under Consideration, 3-month Quarterly Average, Q1 2019 – Q4 2023




Source: IMC analysis of pCPA data collected from <https://www.pcpacanada.ca/negotiations>.

## pCPA Total Time, All Drugs



## Negotiations on BPG target



**BPG – Brand  
Process Guidelines**

**N = number of completed negotiations**

Source: IMC analysis of pCPA data collected from <https://www.pcpacanada.ca/negotiations>.